Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

After rapid expansion, signs of a slowdown raise questions about future opportunities in the sector When it emerged that ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...